Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>Semiconductors reclaimed the lead in September.</li><li>The WTR AI Index rose 3.0% M/M, above the S&amp;P 500 (down 0.5%) and the Russell 2000 (down 5.4%) and in line with the Nasdaq (up 3.2%).</li><li>Semiconductors (20% of the index) jumped 14.5% and accounted for most of the index’s gain, while Software (23%) slipped 1.0%, Internet and Data Services (8%) rose 2.9%, Other Tech (23%) rose 2.6%, and Other Industries (26%) fell 0.9%.</li></ul>

Semiconductors reclaimed the lead in September.The WTR AI Index rose 3.0% M/M, above the S&amp;P 500 (down 0.5%) and the Russell 2000 (down 5.4%) and in line with the Nasdaq (up 3.2%).Semiconductors (20% of the index) jumped 14.5% and accounted for most of the index’s gain, while Software (23%) slipped 1.0%, Internet and Data Services (8%) rose 2.9%, Other Tech (23%) rose 2.6%, and Other Industries (26%) fell 0.9%.

AI Flow Index : Sailing a Sea of Companies in AI - 5 October 2026

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Pacific Biosciences Of California / Equity Bottom-Up

Pacific Biosciences Of California (PACB US)

<ul>
 <li>Pacific Biosciences is a key player in the high-growth, long-read DNA sequencing market with its highly accurate HiFi sequencing technology, positioning it to capitalize on the shift from short-read to long-read applications in research and clinical settings.</li>
 <li>The company faces significant financial headwinds, characterized by a consistent lack of profitability, substantial cash burn, and the recent lowering of its 2026 revenue guidance, which has pushed its cash flow breakeven target to 2028.</li>
 <li>Intense competition from the dominant short-read provider, Illumina, and other long-read players like Oxford Nanopore, coupled with a challenging funding environment for its customers, creates a high-risk, high-reward investment profile.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Pacific Biosciences is a key player in the high-growth, long-read DNA sequencing market with its highly accurate HiFi sequencing technology, positioning it to capitalize on the shift from short-read to long-read applications in research and clinical settings.
  The company faces significant financial headwinds, characterized by a consistent lack of profitability, substantial cash burn, and the recent lowering of its 2026 revenue guidance, which has pushed its cash flow breakeven target to 2028.
  Intense competition from the dominant short-read provider, Illumina, and other long-read players like Oxford Nanopore, coupled with a challenging funding environment for its customers, creates a high-risk, high-reward investment profile.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Pacific Biosciences Of California (PACB US) - Aug 2026

External broker reports(aggregated public sources), Topline Securities

Topline Securities

External broker reports(aggregated public sources)

Topline Securities is one of the fastest growing brokerage houses in Pakistan. It has strong equity brokerage, economic / equity research, mutual fund distribution, commodity trading and corporate finance & advisory functions. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Macroeconomics

<ul><li>The government has notified SRO 1064(I)/2026 (superseding SRO 1152(I)/2025), effective July 1, 2026, implementing the second-year tariff rationalization plan under the National Tariff Policy (NTP) 2025–30.</li><li>The government has reduced Regulatory Duty (RD) across almost all categories, with the maximum RD now capped at 20% vs earlier 50%.</li><li>To highlight, the highest RD slab previously stood at 50%, applicable to various automobile categories (PCT 8703) for import of SUVs, 4x4s, and other large-engine vehicles.</li></ul>

The government has notified SRO 1064(I)/2026 (superseding SRO 1152(I)/2025), effective July 1, 2026, implementing the second-year tariff rationalization plan under the National Tariff Policy (NTP) 2025–30.The government has reduced Regulatory Duty (RD) across almost all categories, with the maximum RD now capped at 20% vs earlier 50%.To highlight, the highest RD slab previously stood at 50%, applicable to various automobile categories (PCT 8703) for import of SUVs, 4x4s, and other large-engine vehicles.

Pakistan Strategy: Govt Slashes Import Duties Under Second Phase of NTP 2025–30; Sector Wise Impact of Tariff Rationalization

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We downgraded our near-term outlook on SPX and QQQ to neutral last week (11/19/25), after being bullish since 4/22/25, while we maintained our intermediate-term bullish outlook (as of 5/14/25).</li>
<li>Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are back to being near-term bullish as long as these supports continue to hold</li>
<li>The latest pullback offers an attractive entry point into all the speculative growth areas that we were pounding the table on since May, WITH A STOP AT LAST WEEKS LOWS</li>
</ul>


We downgraded our near-term outlook on SPX and QQQ to neutral last week (11/19/25), after being bullish since 4/22/25, while we maintained our intermediate-term bullish outlook (as of 5/14/25).
Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are back to being near-term bullish as long as these supports continue to hold
The latest pullback offers an attractive entry point into all the speculative growth areas that we were pounding the table on since May, WITH A STOP AT LAST WEEKS LOWS


Back to Near-Term Bullish on SPX and Nasdaq 100; Supports Held at SPX 6480-6520 and QQQ $580-583

AlphaSituations-Event/Catalyst Driven Research, AlphaSituations

Robert Sassoon

AlphaSituations-Event/Catalyst Driven Research

AlphaSituations

Since its establishment, AlphaSituations has delivered a track record of outperformance with a hit rate of winners of more than 70% of its portfolio of ideas generating annualized average returns of 20%. In January 2022, AlphaSituations was contracted by Water Tower Research, an investor engagement and stakeholder communication platform to provide coverage of Special Situations

Our snapshot study reveals that abandoned merger targets can deliver even more lucrative investment opportunities once the dust settles. Based on data from our universe of announced US M&amp;A deals in excess of $400MN going back to 2017, when merger transaction terminations do occur (which is not that common), better returns can be achieved out of target companies more often than not.

Our snapshot study reveals that abandoned merger targets can deliver even more lucrative investment opportunities once the dust settles. Based on data from our universe of announced US M&amp;A deals in excess of $400MN going back to 2017, when merger transaction terminations do occur (which is not that common), better returns can be achieved out of target companies more often than not.

MergerTalk:Broken Deals Do Not Necessarily Lead To Broken Investments

United States

Pacific Biosciences of California Inc. has developed a novel approach to studying the synthesis and regulation of DNA, RNA and protein.  The Company's system enables real-time analysis of biomolecules with single molecule resolution.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pacific Biosciences Of California (PACB US)

AI Flow Index : Sailing a Sea of Companies in AI - 5 October 2026

The WTR AI Index rose 3.0% M/M, above the S&P 500 (down 0.5%) and the Russell 2000 (down 5.4%) and in line with the Nasdaq (up 3.2%).

Water Tower Research

Primer: Pacific Biosciences Of California (PACB US) - Aug 2026

Pacific Biosciences is a key player in the high-growth, long-read DNA sequencing market with its highly accurate HiFi sequencing technology,...

αSK Primers

Pakistan Strategy: Govt Slashes Import Duties Under Second Phase of NTP 2025–30; Sector Wise Impact of Tariff Rationalization

The government has notified SRO 1064(I)/2026 (superseding SRO 1152(I)/2025), effective July 1, 2026, implementing the second-year tariff...

Topline Securities

Back to Near-Term Bullish on SPX and Nasdaq 100; Supports Held at SPX 6480-6520 and QQQ $580-583

Back to Near-Term Bullish on $SPX and Nasdaq 100 $NDX; Crucial Supports Held at 6480-6520 on SPX and $580-$583 on $QQQ, we are near-term bullish as...

Vermilion Research

MergerTalk:Broken Deals Do Not Necessarily Lead To Broken Investments

Our snapshot study reveals that abandoned merger targets can deliver even more lucrative investment opportunities more often than one might think

Robert Sassoon

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)